Ivermectin and Cancer
Today, I sent the following information to my brother-in-law, who was recently diagnosed with stage 4 pancreatic cancer. This was after listening to the latest Greg Hunter ‘Watchdog USA’ podcast on turbo cancers and Ivermectin being used to treat certain cancers. I did some research and I found a plethora of peer reviewed studies on this subject. Below I’ve linked 5 of those articles along with some highlights.
I’m sharing this as it might be very useful information to those of you that may either be suffering with a cancer or, know someone who is.
******************************************************
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
https://www.nature.com/articles/s41523-021-00229-5
- Use of the Anti-Parasitic Drug Ivermectin to Treat Breast Cancer
Seeking such an agent among FDA-approved drugs, our group found that ivermectin, an anti-parasitic drug used worldwide since 1975 to treat close to 1 billion people primarily for river blindness and other parasitic infections, promotes ICD in breast cancer cells. Among our other findings was evidence that ivermectin modulates the P2X4/P2X7 purinergic pathway, suggesting that ivermectin may further harness tumors’ intrinsic high extracellular levels of ATP for anti-cancer activity.
- Ivermectin, a potential anticancer drug derived from an antiparasitic drug
Highlights
- Ivermectin effectively suppresses the proliferation and metastasis of cancer cells and promotes cancer cell death at doses that are nontoxic to normal cells.
- Ivermectin shows excellent efficacy against conventional chemotherapy drug-resistant cancer cells and reverses multidrug resistance.
- Ivermectin combined with other chemotherapy drugs or targeted drugs has powerful effects on cancer.
- The structure of crosstalk centered on PAK1 kinase reveals the mechanism by which ivermectin regulates multiple signaling pathways.
- Ivermectin has been used to treat parasitic diseases in humans for many years and can quickly enter clinical trials for the treatment of tumors.
https://www.sciencedirect.com/science/article/pii/S1043661820315152
- Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway
Methods
We used two solid tumor cell lines (HCT-8 colorectal cancer cells and MCF-7 breast cancer cells) and one hematologic tumor cell line (K562 chronic myeloid leukemia cells), which are resistant to the chemotherapeutic drugs vincristine and adriamycin respectively, and two xenograft mice models, including the solid tumor model in nude mice with the resistant HCT-8 cells and the leukemia model in NOD/SCID mice with the resistant K562 cells to investigate the reversal effect of IVM on the resistance in vitro and in vivo. MTT assay was used to investigate the effect of IVM on cancer cells growth in vitro. Flow cytometry, immunohistochemistry, and immunofluorescence were performed to investigate the reversal effect of IVM in vivo. Western blotting, qPCR, luciferase reporter assay and ChIP assay were used to detect the molecular mechanism of the reversal effect. Octet RED96 system and Co-IP were used to determine the interactions between IVM and EGFR.
Results
Our results indicated that ivermectin at its very low dose, which did not induce obvious cytotoxicity, drastically reversed the resistance of the tumor cells to the chemotherapeutic drugs both in vitro and in vivo. Mechanistically, ivermectin reversed the resistance mainly by reducing the expression of P-glycoprotein (P-gp) via inhibiting the epidermal growth factor receptor (EGFR), not by directly inhibiting P-gp activity. Ivermectin bound with the extracellular domain of EGFR, which inhibited the activation of EGFR and its downstream signaling cascade ERK/Akt/NF-κB. The inhibition of the transcriptional factor NF-κB led to the reduced P-gp transcription.
Conclusions
These findings demonstrated that ivermectin significantly enhanced the anti-cancer efficacy of chemotherapeutic drugs to tumor cells, especially in the drug-resistant cells. Thus, ivermectin, a FDA-approved antiparasitic drug, could potentially be used in combination with chemotherapeutic agents to treat cancers and in particular, the drug-resistant cancers.
https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1251-7
- Ivermectin, a potential anticancer drug derived from an antiparasitic drug
Ivermectin has powerful antitumor effects, including the inhibition of proliferation, metastasis, and angiogenic activity, in a variety of cancer cells. This may be related to the regulation of multiple signaling pathways by ivermectin through PAK1 kinase. On the other hand, ivermectin promotes programmed cancer cell death, including apoptosis, autophagy and pyroptosis. Ivermectin induces apoptosis and autophagy is mutually regulated. Interestingly, ivermectin can also inhibit tumor stem cells and reverse multidrug resistance and exerts the optimal effect when used in combination with other chemotherapy drugs.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/
This article has been archived for your research. The original version from The Burning Platform can be found here.
